Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

doi:10.1593/neo.09814

Article

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Neoplasia (New York, N.Y.) - 1 Oct 2009

Marchetti Antonio, Milella Michele, Felicioni Lara, Cappuzzo Federico, Irtelli Luciana, Del Grammastro Maela, Sciarrotta Mariagrazia, Malatesta Sara, Nuzzo Carmen, Finocchiaro Giovanna, Perrucci Bruno, Carlone Donatella, Gelibter Alain J, Ceribelli Anna, Mezzetti Andrea, Iacobelli Stefano, Cognetti Francesco, Buttitta Fiamma

Abstract excerpt

Mutations inducing resistance to anti-epidermal growth factor receptor (EGFR) therapy may have a clinical impact even if present in minor cell clones which could expand during treatment. We tested this hypothesis in lung cancer patients treated with tyrosine kinase inhibitors (TKIs). Eighty-three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

Abstract excerpt

Topics

Related research